Clinical approach to recognizing and managing a patient with vaginal atrophy: A guide for Physician Assistants

Internet Journal of Academic Physician Assistants

Volumn 8, Issue 1, 2010, Pages

  Lehman, Rebecca A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Diagnosis; Hormonal therapy; Treatment; Vaginal atrophy

Indexed keywords

EID: 78649361325     PISSN: 10924078     EISSN: 10924078     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Santoro N, Komi J: Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med; 2009; 6: 2133-2142. (s)
2. Pastore LM, Carter RA, Hulka BS, Wells E: Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas; 2004; 49: 292-303. (s)
3. North American Menopause Society: The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause; 2007; 14: 355-369. (s)
4. Bachmann GA, Nevadunsky NS: Diagnosis and treatment of atrophic vaginitis. Am Fam Physician; 2000; 61: 3090-3096. (s)
5. Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M: Hormones and sexuality during transition to menopause. Obstet Gynecol; 2007; 109: 831-840. (s)
6. Levine KB, Williams RE, Hartmann KE: Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause; 2008; 15: 661-666. (s)
7. Molander U, Milsom I, Ekelund P, Mellstrom D: An epidemiological study of urinary incontinence and related urogenital symptoms in elderly women. Maturitas; 1990; 12: 51-60. (s)
8. American College of Obstetricians and Gynecologists: Genitourinary tract changes. Obstet Gynecol; 2004; 104: 56S-61S. (s)
9. Cohen BL, Barboglio P, Gousse A: The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med; 2008; 5: 1418-1423. (s)
10. Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A: The detection and management of vaginal atrophy. J Obstet Gynaecol Can; 2004; 26: 503-515. (s)
11. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ: A study of sexuality and health among older adults in the United States. N Engl J Med; 2007; 357: 762-774. (s)
12. Freedman MA: Vaginal pH, estrogen and genital atrophy. Menopause Manag; 2008; 17: 9-11. (s)
13. Goldstein I: Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med; 2007; 4 Suppl 3: 235-253. (s)
14. Nelson HD: Menopause. Lancet; 2008; 371: 760-770. (s)
15. Mehta A, Bachmann G: Vulvovaginal complaints. Clin Obstet Gynecol; 2008; 51: 549-555. (s)
16. Resnick NM: An 89-year-old woman with urinary incontinence. JAMA; 1996; 276: 1832-1840. (s)
17. Lovatsis D, Drutz HP: The role of estrogen in female urinary incontinence and urogenital aging: a review. Ostomy Wound Manage; 1998; 44: 48-53. (s)
18. North American Menopause Society: Common clinical issues during perimenopause and beyond. In: Menopause Practice: A Clinician's Guide 3rd ed. Cleveland, OH: North American Menopause Society; 2007: 29-101. (s)
19. Baron JA, La Vecchia C, Levi F: The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol; 1990; 162: 502-514. (s)
20. Karamanidis D, Tamiolakis D, Koutsougeras G, Tripsanas CH, Retzos K, Karidis S, Liberis B: Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women. Clin Exp Obstet Gynecol; 2001; 28: 274-276. (s)
21. Bachmann GA, Leiblum SR: The impact of hormones on menopausal sexuality: a literature review. Menopause; 2004; 11: 120-130. (s)
22. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD: Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas; 2005; 52 Suppl 1: S46-S52. (s)
23. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W: Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol; 2008; 112: 1053-1060. (s)
24. Friedrich EG: Vaginitis 2nd. Philadelphia, PA: WB Saunders Co.; 1983: 9-33. (s)
25. Society of Obstetricians and Gynaecologists of Canada: The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet; 2005; 88: 222-228. (s)
26. van der Laak JA, de Bie LM, de Leeuw H., de Wilde PC, Hanselaar AG: The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol; 2002; 55: 446-451. (s)
27. Palacios S: Managing urogenital atrophy. Maturitas; 2009; 63: 315-318. (s)
28. Robb-Nicholson C: My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree? Harv Womens Health Watch; 2007; 15: 7. (s)
29. North American Menopause Society: Vulvovaginal symptoms. In: Menopause Guidebook 6th ed. Cleveland, OH: North American Menopause Society; 2006: 19-21. (s)
30. Yildirim B, Kaleli B, Duzcan E, Topuz O: The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas; 2004; 49: 334-337. (s)
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA; 2002; 288: 321-333. (s)
32. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA; 2004; 291: 1701-1712. (s)
33. Freedman M: Sexuality in post-menopausal women. Menopausal Med; 2000; 8: 1-5. (s)
34. McCoy NL: Female sexuality during aging. In: Functional Neurobiology of Aging. Hof R and Mobbs CV eds. New York, NY: Academic Press; 2001: 769-779. (s)
35. Sarrel PM: Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med; 2000; 9 Suppl 1: S25-S32. (s)
36. Galhardo CL, Soares JM, Jr., Simoes RS, Haidar MA, Rodrigues de LG, Baracat EC: Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol; 2006; 33: 85-89. (s)
37. Shulman LP, Portman DJ, Lee WC, Balu S, Joshi AV, Cobden D, Wang Q, Pashos CL: A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt); 2008; 17: 569-578. (s)
38. North American Menopause Society: Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause; 2007; 14: 168-182. (s)
39. Nilsson K, Heimer G: Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinetic and pharmacodynamic study. Maturitas; 1992; 15: 121-127. (s)
40. Barentsen R, van de Weijer PHM, Schram JHN: Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol; 1997; 71: 73-80. (s)
41. Crandall C: Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Womens Health; 2002; 11: 857-877. (s)
42. Suckling JA, Kennedy R, Lethaby A, Roberts H: Local oestrogen for vaginal atrophy in postmenopausal women (review). Cochrane Database Syst Rev; 2006; 4: 1-91. (s)
43. Raz R, Stamm WE: A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med; 1993; 329: 753-756. (s)
44. Palacios S, Castelo-Branco C, Cancelo MJ, Vazquez F: Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas; 2005; 50: 98-104. (s)
45. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A: The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res; 2001; 27: 255-260. (s)
46. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser I: Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric; 2005; 8: 83-93. (s)
47. Nachtigall LE: Clinical trial of the estradiol vaginal ring in the U.S. Maturitas; 1995; 22 Suppl: S43-S47. (s)
48. Mainini G, Scaffa C, Rotondi M, Messalli EM, Quirino L, Ragucci A: Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17b-estradiol vaginal tablets. Clin Exp Obstet Gynecol; 2005; 32: 111-113. (s)
49. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M: Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol; 2008; 111: 67-76. (s)
50. Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, Klein KO: Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause; 2002; 9: 179-187. (s)
51. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS: 17b-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause; 2000; 7: 156-161. (s)
52. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E: Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand; 2000; 79: 293-297. (s)
53. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Fraser IS: A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol; 1996; 103: 351-358. (s)
54. Cicinelli E: Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol; 2008; 22: 391-405. (s)
55. Bachmann GA, Schaefers M, Uddin A, Utian WH: Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause; 2009; 16: 877-882. (s)
56. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J: Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause; 2009; 16: 907-922. (s)
57. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H: Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause; 2009. (s)
58. Simon JA: Vulvovaginal atrophy: new and upcoming approaches. Menopause; 2009; 16: 5-7. (s)
59. Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev; 2003; CD001500. (s)